Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemo-embolization on serum fibrosis indicators and survival of liver cancer patients.

Abstract

OBJECTIVES:

To explore the impact of low- vs conventional-dose chemotherapy via transcatheter arterial chemo-embolization (TACE) on serum fibrosis indicators and treatment efficacy of hepatocellular cancer patients (HCC).

MATERIALS AND METHODS:

Patients fulfilling the eligibility criteria were assigned to TACE in Group A (with low-dose chemotherapy) or Group B (conventional-dose chemotherapy). Four serum fibrosis related indicators, hyaluronic acid(HA), human pro-collagen type-III (hPC-III), laminin (LN), and collagen type-IV(IV-C) before TACE were compared with the values 7 days after TACE. The response rate and survival time were also compared between the two groups.

RESULTS:

Fifty patients with HCC were enrolled in this study, including 25 in Group A and 25 in Group B. No significant differences were detected between the two groups in the four indicators before TACE. After TACE, the value of the four serum indicators increased significantly in Group B. However, no significant differences regarding these four indicators were found in Group A after TACE. Significant differences were demonstrated between the two groups after TACE, but median survival time and 1 or 2 year overall survival rates did not differ (P>0.05).

CONCLUSIONS:

Low-, compared with conventional-dose chemotherapy exerts the same impact on the variation of fibrosis related indicators and has no influence on median survival time and survival rate after TACE in HCC patients.

• Authors: Wei-Dong Kong, Jian-Ming Cao, Jian Xu, Bo Chen, Tao Yang, Tan-Tan Xu, Guang-Ming Lu, Jun Li, Xin-En Huang
• Journal: Asian Pacific journal of cancer prevention : APJCP (Asian Pac J Cancer Prev) Vol. 13 Issue 9 Pg. 4757-61 ( 2012) ISSN: 2476-762X [Electronic] Thailand
• PMID: 23167415 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Collagen Type III
• Collagen Type IV
• Laminin
• Epirubicin
• Ethiodized Oil
• Hyaluronic Acid
• Cisplatin
• Fluorouracil

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Carcinoma, Hepatocellular (therapy)
• Chemoembolization, Therapeutic
• Chi-Square Distribution
• Cisplatin (administration & dosage)
• Collagen Type III (blood)
• Collagen Type IV (blood)
• Epirubicin (administration & dosage)
• Ethiodized Oil (administration & dosage)
• Female
• Fluorouracil (administration & dosage)
• Humans
• Hyaluronic Acid (blood)
• Kaplan-Meier Estimate
• Laminin (blood)
• Liver Cirrhosis (blood, chemically induced)
• Liver Neoplasms (therapy)
• Male
• Middle Aged